Compare DINO & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DINO | PCVX |
|---|---|---|
| Founded | 1947 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 8.4B |
| IPO Year | 2022 | 2020 |
| Metric | DINO | PCVX |
|---|---|---|
| Price | $61.02 | $60.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $60.27 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 2.2M | 1.1M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.27% | N/A |
| EPS Growth | ★ 238.46 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.23 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.66 | $28.09 |
| 52 Week High | $64.70 | $65.00 |
| Indicator | DINO | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 57.93 | 61.81 |
| Support Level | $47.04 | $42.30 |
| Resistance Level | $64.70 | $65.00 |
| Average True Range (ATR) | 2.30 | 2.19 |
| MACD | -0.19 | 0.54 |
| Stochastic Oscillator | 52.08 | 92.07 |
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 300 distributors and 1,500 wholesale branded sites across 30 states. It also owns and operates 4,400 miles of petroleum product pipelines and terminals principally in the southwestern United States.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.